RINVOQ vs UPADACITINIB
Independent side-by-side comparison.
Rating
72/100
68/100
Pharmacy pays
—
—
Type
RX
RX
Active ingredient
UPADACITINIB
UPADACITINIB
Dosage forms
Solution, Tablet, extended release
Tablet, extended release, Tablet
Drug class
Janus Kinase Inhibitor
Janus Kinase Inhibitor
Boxed warning
None
Half-life
about 8 to 14 hours (mean terminal elimination half-life)
about 8 to 14 hours (mean terminal elimination half-life)
Treats
Rheumatoid Arthritis
Rheumatoid Arthritis
Frequently asked questions
Which is better-rated, Rinvoq or Upadacitinib?
By our independent rating, Rinvoq scores higher — 3.6 vs 3.4 out of 5 for Upadacitinib. Ratings are based on FDA regulatory (recall-safety) data.
What is the difference between Rinvoq and Upadacitinib?
Both Rinvoq and Upadacitinib share the active ingredient Upadacitinib.
Ratings are based on FDA regulatory (recall-safety) data. This comparison is for general reference only — not medical advice. Always consult a licensed professional before choosing or switching a medication.